Source:http://linkedlifedata.com/resource/pubmed/id/20022192
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2010-3-15
|
| pubmed:abstractText |
CEM-101 is a novel fluoroketolide with reported high potency against diverse groups of Gram-positive (Micrococcus spp., viridans group streptococci, Corynebacterium spp. Listeria monocytogenes, Clostridium spp., etc.) and Gram-negative bacteria (Neisseria gonorrhoeae, Campylobacter jejuni, Helicobacter pylori, Bacteroides fragilis, Shigella spp., etc.), including mycoplasma and ureaplasma, as well as bacteria commonly associated with community-acquired respiratory tract infections and skin and skin structure infections. In this study, CEM-101 and comparator antimicrobials were tested against a collection of very low prevalence aerobic and anaerobic bacteria collected via the SENTRY Antimicrobial Surveillance Program platform. CEM-101 was highly active against all Gram-positive organisms (MIC(50), 0.015 microg/mL) as compared with telithromycin (MIC(50), 0.06 microg/mL), clarithromycin (MIC(50), 0.12 microg/mL), and erythromycin (MIC(50), 0.25 microg/mL). Among Gram-negative pathogens, CEM-101 also displayed a high potency against most strains (MIC(50), 4 microg/mL) but was found to be equivalent or less active when compared with other antimicrobials tested with MIC(50) values ranging from < or =0.12 microg/mL for levofloxacin to 8 microg/mL for telithromycin. Among the strict anaerobic species, CEM-101 activity mirrored that of the aerobic species: high activity against the Gram-positive anaerobes (MIC(50) results ranging from < or =0.03 microg/mL to 0.12 microg/mL) and equivalent or less susceptible against Gram-negative anaerobes. Our in vitro antimicrobial susceptibility results for CEM-101 demonstrate better activity compared with other MLS(B) class agents among a diverse group of uncommonly isolated bacterial pathogens; these results provide an impetus for possible expanded indications during Phase 2 and 3 clinical trials.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1879-0070
|
| pubmed:author | |
| pubmed:copyrightInfo |
2010 Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
66
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
393-401
|
| pubmed:meshHeading |
pubmed-meshheading:20022192-Anti-Bacterial Agents,
pubmed-meshheading:20022192-Bacteria, Aerobic,
pubmed-meshheading:20022192-Bacteria, Anaerobic,
pubmed-meshheading:20022192-Bacterial Infections,
pubmed-meshheading:20022192-Gram-Negative Bacteria,
pubmed-meshheading:20022192-Gram-Positive Bacteria,
pubmed-meshheading:20022192-Humans,
pubmed-meshheading:20022192-Macrolides,
pubmed-meshheading:20022192-Microbial Sensitivity Tests,
pubmed-meshheading:20022192-Molecular Structure,
pubmed-meshheading:20022192-Triazoles
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
|
| pubmed:affiliation |
JMI Laboratories, North Liberty, IA 52317, USA. shan-putnam@jmilabs.com
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|